openPR Logo
Press release

Coronary Artery Disease Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

10-22-2024 10:48 PM CET | Health & Medicine

Press release from: ABNewswire

Coronary Artery Disease Pipeline Therapeutics, Assessment,

DelveInsight's, "Coronary Artery Disease Pipeline Insight 2024" report provides comprehensive insights about 30+ Coronary Artery Disease companies and 25+ pipeline drugs in Coronary Artery Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. Coronary Artery Disease pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Coronary Artery Disease Research. Learn more about our innovative pipeline today! @ Coronary Artery Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Coronary Artery Disease Pipeline Report

* In October 2024:- Novarits Pharmaceuticals- The purpose of this study is to evaluate the efficacy of inclisiran compared to placebo on top of maximally tolerated dose of statin therapy in reducing total coronary atheroma volume assessed by CCTA in participants with a diagnosis of Non-Obstructive Coronary Artery Disease (NOCAD) without previous cardiovascular events, who have an LDL-C greater than or equal to 55 mg/dL (1.4 mmol//L), no significant pressure drop in Fractional Flow Reserve Computed Tomography (FFRCT) and a CT-adapted Leaman score >5 despite the use of maximally tolerated statin therapy(and if applicable, another LLT on top of statin therapy for at least 30 days in up to 20% of randomized participants).
* In October 2024:- CSL Behring- This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double blind, placebo controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on CV outcomes and safety in subjects with ASCVD or diabetes mellitus and evidence of systemic inflammation who are undergoing maintenance dialysis.
* In October 2024:- DalCor Pharmaceuticals- This is an event-driven study and will last until approximately 200 subjects have experienced a primary event, unless the study is stopped at the planned interim analysis. Visits after randomization will be performed as virtual visits where permissible every 3 months or as clinic visits until the study is stopped. For any subject prematurely discontinuing study medication, assessments will be conducted every 3 months for the collection of study endpoints.
* DelveInsight's Coronary Artery Disease pipeline report depicts a robust space with 30+ active players working to develop 25+ pipeline therapies for Coronary Artery Disease treatment.
* The leading Coronary Artery Disease Companies such as Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, AstraZeneca, Helixmith, Amgen, Angionetics, Xylocor Therapeutics, Regio Biosciences , and others.
* Promising Coronary Artery Disease Therapies such as Inclisiran sodium 300 mg, Lansoprazole 15 mg, DFV890, Evolocumab, Regadenoson, Sarpogrelate Sustained Release/Aspirin, Tirzepatide , and others.

Stay informed about the cutting-edge advancements in Coronary Artery Disease Treatments. Download for updates and be a part of the revolution in cancer care @ Coronary Artery Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Coronary Artery Disease Emerging Drugs

* Flurpiridaz F-18: GE Healthcare

Flurpiridaz F-18, a fluorine 18-labeled agent was developed by Lantheus Medical Imaging for the diagnosis of coronary artery disease (CAD), the most common form of heart disease. Flurpiridaz F 18 is an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent. GE Healthcare has launched a second Phase III clinical trial for the use of Flurpiridaz 18F Injection in PET myocardial perfusion imaging (MPI) to detect CAD. Currently, it is in Phase III stage of clinical trial evaluation to treat Coronary Artery Disease.

* Evolocumab: Amgen

Evolocumab injection is used to reduce the risk of a stroke or heart attack or the need for coronary artery bypass (CABG) surgery in people with cardiovascular disease. Evolocumab injection is also used along with diet alone or in combination with other cholesterol-lowering medications such as HMG-CoA reductase inhibitors (statins) or ezetimbe (Zetia) to decrease the amount of low-density lipoprotein (LDL) cholesterol ('bad cholesterol') in the blood, including people who have familial heterozygous hypercholesterolemia. It is also used along with diet changes and other treatments to reduce the amount low-density lipoprotein (LDL) cholesterol in the blood in people that have homozygous familial hypercholesterolemia. It is in a class of medications called proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor monoclonal antibody. It works by blocking the production of LDL cholesterol in the body to decrease the amount of cholesterol that may build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body. Currently, it is in Phase III stage of clinical trial evaluation to treat Coronary Artery Disease.

* Revacept: advanceCor

Revacept seals the lesion in a blood vessel like a plaster. It acts locally at the ruptured plaque instead of involving the complete organism, as is the case for all established drugs. Revacept has proven to be very effective in laboratory tests with platelets and in animal experiments. In a Phase I clinical trial with volunteers, it was shown to be very well tolerated at all dosages. It induced a specific and dose-dependent inhibition of aggregation (clumping of platelets) in the blood of the volunteers without any relevant side effects. In particular, general haemostasis was not affected: The bleeding time was not prolonged by Revacept and there were no bleeding complications and no reduction in platelet count (thrombopenia). Currently, it is in Phase II stage of clinical trial evaluation to treat Coronary Artery Disease.

Learn more about Coronary Artery Disease Drugs opportunities in our groundbreaking Coronary Artery Disease Research and development projects @ Coronary Artery Disease Unmet Needs [https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Coronary Artery Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.

Coronary Artery Disease Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Discover the latest advancements in Coronary Artery Disease Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Coronary Artery Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Coronary Artery Disease Pipeline Report

* Coverage- Global
* Coronary Artery Disease Companies- Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, AstraZeneca, Helixmith, Amgen, Angionetics, Xylocor Therapeutics, Regio Biosciences, and others.
* Coronary Artery Disease Therapies- Inclisiran sodium 300 mg, Lansoprazole 15 mg, DFV890, Evolocumab, Regadenoson, Sarpogrelate Sustained Release/Aspirin, Tirzepatide, and others.
* Coronary Artery Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Coronary Artery Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Coronary Artery Disease Pipeline on our website @ Coronary Artery Disease Drugs and Companies [https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Coronary Artery Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Coronary Artery Disease - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Evolocumab: Amgen
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Ninerafaxstat: Imbria Pharmaceuticals, Inc.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Coronary Artery Disease Key Companies
* Coronary Artery Disease Key Products
* Coronary Artery Disease- Unmet Needs
* Coronary Artery Disease- Market Drivers and Barriers
* Coronary Artery Disease- Future Perspectives and Conclusion
* Coronary Artery Disease Analyst Views
* Coronary Artery Disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=coronary-artery-disease-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Coronary Artery Disease Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here

News-ID: 3705260 • Views:

More Releases from ABNewswire

Medical Clinic Documents Significant Recovery Rates in Peripheral Neuropathy Patients Using Advanced IV Therapy
Medical Clinic Documents Significant Recovery Rates in Peripheral Neuropathy Pat …
Los Angeles medical facility documents significant recovery rates in peripheral neuropathy patients using EBOO blood oxygenation technology, showing measurable improvements in sensation restoration and symptom relief. LOS ANGELES, CA - Ebo2 Therapy and Wellness | Los Angeles [http://index.businessinsurance.com/businessinsurance/article/abnewswire-2025-8-21-local-eboo-clinic-achieves-95-patient-satisfaction-rate-making-specialized-iv-therapy-near-me-more-accessible-than-ever] has documented notable recovery outcomes in patients suffering from peripheral neuropathy through specialized blood oxygenation treatments. The medical facility's recent patient data reveals substantial improvements in sensation restoration and symptom management using Extracorporeal
East Texas Roofers Launch Community Roof Health Assessment Program to Prevent Weather-Related Emergencies
East Texas Roofers Launch Community Roof Health Assessment Program to Prevent We …
Guardian Roofing Pros launches community roof health assessment program across East Texas, helping homeowners prevent weather emergencies through proactive roof evaluations and maintenance planning. Guardian Roofing Pros [http://index.businessinsurance.com/businessinsurance/article/abnewswire-2025-8-20-guardian-roofing-pros-expands-service-excellence-among-roofing-companies-in-flint-tx-with-enhanced-storm-damage-solutions] has announced the launch of a comprehensive community roof health assessment program designed to help East Texas homeowners identify potential vulnerabilities before severe weather strikes. This proactive initiative addresses the growing need for preventive maintenance in the region, where extreme weather events have
Floral Concepts - Houston Expands Wedding Flowers Consultation Services Following Rise in Custom Requests
Floral Concepts - Houston Expands Wedding Flowers Consultation Services Followin …
Floral Concepts - Houston adds extended consultation services responding to increased customer requests. Local couples drive demand for personalized designs and seasonal specialty blooms. A notable shift in how couples approach floral arrangements for their special day has prompted Floral Concepts - Houston [http://index.businessinsurance.com/businessinsurance/article/abnewswire-2025-8-22-floral-concepts-houston-celebrates-over-five-decades-as-premier-florist-with-expanded-services] to expand its consultation services. The Houston-based florist Houston operation reports a significant increase in requests for personalized designs, reflecting broader trends in the local wedding industry. Located
Augusta Auto Detailing Company Reports 90% Water Reduction Through Mobile Service Model
Augusta Auto Detailing Company Reports 90% Water Reduction Through Mobile Servic …
Marco's Magnificent Mobile Detailing reports 90% water reduction through the mobile service model, using 5 gallons versus 50 gallons per vehicle. Augusta company serves 13 locations with eco-friendly detailing and ceramic coating options. Marco's Magnificent Mobile Detailing [http://index.businessinsurance.com/businessinsurance/article/abnewswire-2025-6-16-marcos-magnificent-mobile-auto-detailing-receives-best-detailing-in-ga-nomination-for-mobile-service-excellence] has documented significant water conservation achievements through its mobile service approach, reducing water consumption from 50 gallons per vehicle to just 5 gallons. The Augusta-based company's environmental impact data reveals how mobile auto

All 5 Releases


More Releases for Coronary

Top Trends Transforming the Coronary Angiography Devices Market Landscape in 202 …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Coronary Angiography Devices Industry Market Size Be by 2025? The market for coronary angiography devices has seen significant growth recently. It is projected to expand from $9.43 billion in 2024 to $10.1 billion in 2025, with a compound annual growth rate (CAGR) of 7.2%. The growth
Driving Coronary Artery Disease Market Growth in 2025: The Role of The Influence …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Coronary Artery Disease Market Size Growth Forecast: What to Expect by 2025? The market size for coronary artery disease has seen a significant expansion in the past years. A rise from $29.15 billion in 2024, to an estimated $31.97 billion in 2025 at a compound annual growth rate (CAGR)
Major Force in the Coronary Pressure Market 2025: Increasing Cardiovascular Dise …
How Will the Coronary Pressure Market Grow, and What Is the Projected Market Size? In recent years, there has been considerable growth in the size of the coronary pressure market. It is projected to expand from $17.38 billion in 2024 to $19.15 billion in 2025, marking a compound annual growth rate (CAGR) of 10.2%. The growth observed in the historical period is linked to factors such as increased occurrence of cardiovascular
Coronary Balloon Products Market A Less Invasive Path to Open Arteries: The Expa …
Coronary Balloon Products Market worth $1.18 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Coronary Balloon Products Market- (By Product (PTAC balloon, Nc balloon), By Material (Compliant Balloons, Non-Compliant, Semi-Compliant), By End-User (Hospitals, Cardiac Centres, Ambulatory Surgical Centres)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce
Coronary Stent Market - Healthy Hearts, Stronger Lives: Advances in Coronary Ste …
Newark, New Castle, USA: The "Coronary Stent Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Coronary Stent Market: https://www.growthplusreports.com/report/coronary-stent-market/8041 This latest report researches the industry structure, sales, revenue,
Intravascular Ultrasound Systems Market(By Product Type - Ivus Consoles, Ivus Ca …
Intravascular Ultrasound Systems (IVUS) is an imaging method with which we can visualize a coronary artery from the inside out. Intravascular Ultrasound Systems are usually designed in such a way that the individual can have a complete view of the coronary artery blockade using a catheter which is attached to an ultrasound probe at one end and the other end is attached to a computerized ultrasound equipment. The inside out view